Haisco Pharmaceutical Group Co., Ltd.

002653

CNE100001BC7

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 27/05/2024 am IST			5-day change	1st Jan Change
30.31 ^CNY	+1.51%		-1.75%	+30.93%

16/05	Chinese Drug Regulator Accepts Haisco Pharma's Application for Pulmonary Disease Drug	MT
19/04	Haisco Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Xizang Haisco Pharmaceutical Group Co., Ltd. has Changed its Name to Haisco Pharmaceutical Group Co., Ltd

March 04, 2016 at 10:30 am IST

On March 04, 2016, Xizang Haisco Pharmaceutical Group Co., Ltd. changed its name to Haisco Pharmaceutical Group Co., Ltd.

Latest news about Haisco Pharmaceutical Group Co., Ltd.

Chinese Drug Regulator Accepts Haisco Pharma's Application for Pulmonary Disease Drug	16/05	MT
Haisco Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	19/04	CI
Haisco Pharmaceutical Gets Nod to Trial HSK16149 Capsules	18/04	MT
Haisco Pharma Gets Nod to Trial Asthma Drug	10/04	MT
Haisco Pharma Gets Nod to Trial HSK16149 Capsule as Central Neuropathic Pain Drug	01/04	MT
Haisco Pharma's Unit Gets Nod to Trial Drug for Hemolytic Diseases	25/03	MT
Haisco Pharma's Unit Gets Nod to Trial Tumor Drug Candidate	28/02	MT
Haisco Pharma to Set Up New Subsidiary in China’s Tibet Region	18/01	MT
Haisco Pharmaceutical Signs $462 Million Deal with Italy’s Chiesi Farmaceutici	21/11	MT
Haisco Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/23/30	CI
Haisco Pharmaceutical Group Co., Ltd. Announces Management Changes	28/23/28	CI
Haisco Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	16/23/16	CI
Haisco Pharmaceutical's Unit Gets Greenlight to Trial Diabetes Drug	14/23/14	MT
Haisco Pharma's Rupatadine Fumarate Tablets Passes Regulator's Evaluation	02/23/02	MT
Haisco Pharma’s Blood Clot Drug Passes Generic Consistency Evaluation in China	24/23/24	MT
Haisco Pharma Unit Gets Certification for Formula Food	27/23/27	MT
Haisco Pharma Gets Nod for HSK31679 Tablet Trial	26/23/26	MT
Haisco Pharma Unit Registers Nutritional Formula Food	17/23/17	MT
Haisco Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	24/23/24	CI
Haisco Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	17/23/17	CI
Haisco Pharma Unit Gets Certificate for Two Food Supplements	17/23/17	MT
Haisco Pharmaceutical Wins Regulatory Nod to Trial Prostate Cancer Drug	06/23/06	MT
Haisco Pharmaceutical Gets Nod for China Clinical Trial of Lung Cancer Drug; Shares Jump 3%	16/23/16	MT
Haisco Pharmaceutical Wins Nod to Start Phase II Clinical Trial of Liver Disease Drug	15/23/15	MT
Haisco Pharmaceutical Unit's Compound Amino Acid Injection Passes Regulator's Consistency Evaluation; Shares Jump 4%	08/23/08	MT

Chart Haisco Pharmaceutical Group Co., Ltd.

Duration

Period

Chart Haisco Pharmaceutical Group Co., Ltd.

More charts

Haisco Pharmaceutical Group Co.,Ltd., formerly Xizang Haisco Pharmaceutical Group Co., Ltd., is a China-based company principally engaged in the research, development, manufacture and sale of new drugs and high-end medical instrument. The Companyâs main products are categorized into small volume injections, big volume injections, freeze-dried powder injections and others, which include polyene phosphatidylcholine injections, lipid solubility vitamins injection series, doradiazine methanesulfonate injections, nalmefene hydrochloride injections, fluprofen tromethamine tablets and cefoperazone sodium tazobactam sodium for injections, among others. The Company distributes its products in domestic market.

Sector

Pharmaceuticals

Calendar

16/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Haisco Pharmaceutical Group Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

30.11 CNY

Average target price

36.19 CNY

Spread / Average Target

+20.19%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HAISCO PHARMACEUTICAL GROUP CO., LTD.	+30.93%	461.69Cr
ELI LILLY AND COMPANY	+37.87%	73TCr
JOHNSON & JOHNSON	-7.31%	35TCr
MERCK & CO., INC.	+15.92%	33TCr
ABBVIE INC.	+0.44%	28TCr
ASTRAZENECA PLC	+13.32%	24TCr
NOVARTIS AG	+7.10%	21TCr
ROCHE HOLDING AG	-6.63%	20TCr
AMGEN INC.	+4.07%	16TCr
PFIZER, INC.	-1.75%	16TCr

Other Pharmaceuticals

Haisco Pharmaceutical Group Co., Ltd.

Equities

002653

CNE100001BC7

Pharmaceuticals

Xizang Haisco Pharmaceutical Group Co., Ltd. has Changed its Name to Haisco Pharmaceutical Group Co., Ltd

Latest news about Haisco Pharmaceutical Group Co., Ltd.

Chart Haisco Pharmaceutical Group Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for Haisco Pharmaceutical Group Co., Ltd.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals